What question did this study set out to answer?

The aim is to evaluate the effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumors having KIT exon 9 mutations.

February 28, 2026

Adjuvant Imatinib or Observation in Patients With Gastrointestinal Stromal Tumors With KIT Exon 9 Mutations

Q: What does this research mean for the field?

Adjuvant imatinib is associated with delayed recurrence and improved survival in patients with gastrointestinal stromal tumors with KIT exon 9 mutations. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

Puntos clave

The aim is to evaluate the effectiveness of adjuvant imatinib in patients with gastrointestinal stromal tumors having KIT exon 9 mutations.
Conducted a large international cohort study
Included patients with resected GISTs and KIT exon 9 mutations
Analyzed recurrence and survival outcomes after adjuvant imatinib
Adjuvant imatinib was associated with delayed recurrence in patients
Improved overall survival rates were observed
Findings support its use in high-risk GIST patients with specific mutations

Resumen

In this large international cohort study of resected GISTs with KIT exon 9 mutations, adjuvant imatinib was independently associated with delayed recurrence and improved survival. These findings support the use of adjuvant imatinib in mNIH high-risk GISTs with KIT exon 9 mutations and underscore the need for prospective studies to define optimal dosing and treatment duration.

Me gusta

Guardar

Cite This Study

Napolitano et al. (Thu,) studied this question.

synapsesocial.com/papers/69a287350a974eb0d3c02b09 https://doi.org/https://doi.org/10.1001/jamaoncol.2026.0007

Me gusta

Guardar